Kingfish Limited Reports Net Asset Value and Portfolio Composition
Kingfish Limited, a listed investment company managed by Fisher Funds Management Ltd, released its net asset value (NAV) for the period ending 31 October 2026. The NAV, calculated after deducting the value of treasury shares acquired through the company’s buy‑back programme, stood at $1.25 per share. On the same day, the share price closed at $1.10, implying a discount of approximately eleven percent to the NAV.
Portfolio Composition
The company’s investment strategy remains focused on high‑quality growth firms listed on the New Zealand Stock Exchange. The most significant holdings are as follows:
| Holding | Approximate Percentage of Portfolio |
|---|---|
| Fisher & Paykel Healthcare Corporation Limited | ~19 % |
| Infratil | — |
| Mainfreight | — |
| Contact Energy | — |
| Auckland International Airport | — |
While the exact percentages for the remaining positions are not disclosed, the portfolio is diversified across sectors that align with Kingfish’s mandate to deliver capital growth and dividends through a tax‑efficient vehicle.
Governance and Mandate
The recent filing reported no material changes to the company’s governance structure or investment mandate. Kingfish reiterated its commitment to providing investors with broad exposure to the New Zealand market while maintaining disciplined risk management practices.
Market Context
New Zealand equity markets are currently exhibiting caution amid a tightening general election cycle. Broad indices have moderated from a record high reached in August, and the New Zealand dollar has depreciated against the U.S. dollar since late August. Analysts emphasize that the forthcoming election outcome and the subsequent policy agenda will be critical in determining future market performance.
Implications for the Healthcare Sector
The healthcare sector, exemplified by Fisher & Paykel Healthcare, may benefit from potential increases in public health funding and policy shifts that could elevate government spending in this area. Any expansion in health‑sector capital expenditure could enhance the valuation dynamics of companies within the sector, thereby influencing Kingfish’s portfolio performance.
Forward‑Looking Guidance
Kingfish’s full‑year 2027 guidance, released in August, projects continued growth in line with the company’s historical performance. However, broader market uncertainty, driven by political developments and macro‑economic variables, could impact investor sentiment in the near term.
This article synthesizes the company’s disclosed financial metrics, portfolio composition, and prevailing market conditions. It is intended for healthcare professionals and informed investors seeking a data‑driven overview of Kingfish Limited’s recent performance and strategic outlook.
